Testing effectiveness (Phase 2)Study completedNCT00215202
What this trial is testing
Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)
Who this might be right for
Nonresectable Adrenocortical Carcinoma
Dartmouth-Hitchcock Medical Center 16